Mymetics is focused on two pathways to develop prophylactic vaccines:

  • The ability to build a first line of defence against viruses entering the blood stream by focusing on the mucosal layer.
  • The development of a new vaccine delivery platform that does not use live attenuated or killed pathogens, while increasing the immunogenicity and stability of the vaccine.

Using these two pathways, our pipeline comprises vaccine candidates at various stages of clinical development.

Our vaccine candidates for HIV/AIDS, malaria and the intra-nasal influenza are based upon the influenza virosomes, thereby using the influenza virosome as the carrier. While the RSV vaccine candidate is based on their own natural virus and used directly as the vaccine.

Mymetics is focused on two pathways to develop prophylactic vaccines:


Two highly contagious viruses, with a high prevalence in developed countries, causing respiratory tract infections in patients of all ages. While seasonal Flu vaccines, efficacy can be improved and longer and broader protection is sought after. For RSV, there is currently no approved vaccine available.


With over 35 million victims, it is the fourth cause of mortality worldwide. Mymetic's HIV vaccine is the first with a demonstrated ability to prevent viral transmission in primates.


Malaria is an entirely preventable and treatable mosquito-borne illness, but still caused 435,000 deaths in 2017… we are developing a transmission blocking malaria vaccine.


New oncology immunotherapies, especially in the field of check point blockade / inhibitors, have provided significant progress in the treatment of certain cancers. Besides the proven safety and immunogenicity track record of virosome vaccines to generate antibodies, Mymetics’ virosomes are known to be able to trigger CD4+ and also CD8+ T cells through MHC-I presentation, providing an excellent platform to improve cancer immune therapies.


Chikungunya virus (CHIKV) is transmitted by several species of mosquitos, which also are known to transmit Yellow Fever, Dengue and Zika. Symptoms of Chikungunya include joint pain, swelling and stiffness of the joints, headache, fatigue, nausea, rash and fever. Arthritis is the most common direct consequence of infection.